Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | KDM6B | O15054 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9697629 | 0.78 | MAPT (0.60) | PKMMAPTKDM4EKMT2AMEN1 | |
| SCHEMBL5124123 | 0.76 | PKM (0.41) | PKMMAPTKDM4EKMT2AMEN1 | |
| SCHEMBL17594977 | 0.76 | PKM (0.41) | PKMMAPTKDM4EGAAKMT2A | |
| SCHEMBL23160932 | 0.73 | HTT (0.47) | PKMMAPTKDM4EGAAKMT2A | |
| SCHEMBL13827867 | 0.72 | — | — | |
| SCHEMBL1908212 | 0.72 | MEN1 (0.66) | PKMMAPTKMT2AMEN1POLB | |
| SCHEMBL142843 | 0.72 | PKM (0.41) | PKMMAPTKDM4EGAAKMT2A | |
| SCHEMBL9878843 | 0.71 | ADORA1 (0.44) | PKMMAPTKDM4EKMT2APOLB | |
| SCHEMBL798506 | 0.69 | PKM (0.58) | PKMMAPTKDM4EGAAKMT2A | |
| SCHEMBL5038081 | 0.68 | MAPK14 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8733919-B2 | Active energy ray-curable ink composition, inkjet recording method, and inkjet printed article | FUJIFILM CORPORATION (JP) | 2014-05-27 | — | — | US | disclosed |
| US-8529045-B2 | Ink set and image forming method | FUJIFILM CORPORATION (JP) | 2013-09-10 | — | — | US | disclosed |
| EP-2447266-B1 | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator | GLAXO GROUP LTD (GB) | 2013-06-12 | — | — | EP | disclosed |
| US-8354416-B2 | 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| US-8207176-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| EP-2447266-A1 | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator | GLAXO GROUP LIMITED (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120056930-A1 | ACTIVE ENERGY RAY-CURABLE INK COMPOSITION, INKJET RECORDING METHOD, AND INKJET PRINTED ARTICLE | FUJIFILM CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120056930-A1 | ACTIVE ENERGY RAY-CURABLE INK COMPOSITION, INKJET RECORDING METHOD, AND INKJET PRINTED ARTICLE | FUJIFILM CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110057987-A1 | INK SET AND IMAGE FORMING METHOD | FUJIFILM CORPORATION (JP) | 2011-03-10 | — | — | US | disclosed |
| US-20110057987-A1 | INK SET AND IMAGE FORMING METHOD | FUJIFILM CORPORATION (JP) | 2011-03-10 | — | — | US | disclosed |
| EP-1868611-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007147104-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007147103-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| EP-1866311-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | disclosed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| US-20060235029-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006104915-A2 | 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | CBR3, CBR1, CYP2S1 | PKM 3951/4885MAPT 4841/4885KDM4E 4066/4885 |
| US-20060235030-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | PKM 2202/4885MAPT 2802/4885KDM4E 2392/4885 |
| US-20060235029-A1 | Novel compounds | MAPKAPK2, CDC42BPB, MAPK8 | PKM 2431/4885MAPT 2315/4885KDM4E 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.